Corbus Pharmaceuticals Sets Monday September 14 Conference Call for CANYON-1 Phase 1b Topline Data on CRB-913 Peripherally-Restricted CB1 Inverse Agonist for Obesity
Corbus Pharmaceuticals (NASDAQ: CRBP) announced Friday September 11, 2026 that the company will host a conference call and webcast Monday September 14 at 8:00 a.m. EDT to discuss topline data from the Phase 1b CANYON-1 trial of CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up (NCT07310901). Last patient last visit was reported August 4, 2026. Harold Bays MD (investigator) will join the call as a guest speaker. CRB-913 is designed to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve weight-loss efficacy while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). The Monday readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as a differentiated add-on or alternative to the GLP-1 class.